Welcome to our dedicated page for Sonendo news (Ticker: SONX), a resource for investors and traders seeking the latest updates and insights on Sonendo stock.
News for Sonendo, Inc. (SONX) centers on its activities as a commercial-stage medical technology and dental technology company. Sonendo develops and manufactures the GentleWave System, a platform for treating tooth decay and performing root canal therapy by cleaning and disinfecting microscopic spaces within teeth without removing tooth structure. Company news often reiterates this focus on saving teeth from tooth decay and improving clinical outcomes in endodontic care.
Investors and dental professionals following Sonendo’s news can expect regular updates on financial performance, including revenue from GentleWave consoles, procedure instruments and other products, as well as disclosures on gross margin, operating loss, adjusted EBITDA loss and free cash flow burn. The company has reported on a strategic reset and restructuring efforts aimed at stabilizing revenue, expanding margins and reducing operating expenses and cash burn.
Sonendo’s news flow also covers product and technology developments, such as the launch of ProControl for the GentleWave G4 System. This software update is described as enabling optimized cleaning of complex anatomy, increased procedure efficiency and the ability to adjust procedure fluid concentration levels when using the CleanFlow procedure instrument. Such announcements highlight the company’s focus on evolving its GentleWave platform and supporting personalized treatment in endodontics.
Additional news items may include capital-raising and financing transactions, such as private placements of common stock and amendments to credit facilities, as well as strategic transactions like the Asset Purchase Agreement to acquire Biolase assets through a bankruptcy court process and updates on related patent litigation. Leadership and organizational updates, including changes in operational roles, also appear in Sonendo’s press releases. For a consolidated view of these developments, this news page aggregates Sonendo’s public announcements and market-facing communications.
Sonendo reported strong financial results for Q4 2022, with total revenue of $12.2 million, a 24% increase year-over-year, and total revenue for 2022 reaching $41.7 million, up 25% from 2021. Notable growth in consumable revenue was 31% in Q4. The installed base reached 976 units by year-end. Despite this growth, the company faced a net loss of $10.9 million in Q4 and $57.1 million for the full year. Operating expenses rose to $68.7 million, leading to a 58.2 million loss from operations. For 2023, Sonendo anticipates total revenue to be between $48.0 million and $51.0 million.
Sonendo (NYSE: SONX), a leader in dental technology, announces further investments in the specialty of endodontics, focusing on clinical training and education. Since late-2020, Sonendo has supported over 20 endodontic residency programs, training approximately 75 residents to utilize its GentleWave® System, which offers a less painful alternative to traditional root canal treatments. The company is also actively involved in research, with 18 projects ongoing, and sponsors the American Association of Endodontists. In 2022, Sonendo organized over 130 professional education events across North America to enhance clinician knowledge.
Sonendo, Inc. (NYSE: SONX) will release its financial results for Q4 and full year 2022 on March 8, 2023, following market close. A conference call will be held at 1:30 p.m. Pacific Time to discuss these results. Investors can participate by calling (844) 200-6205 or (929) 526-1599, using access code 340170. A live audio webcast will also be available on the company's investor website, with an archived recording accessible for at least 90 days. Sonendo is known for its GentleWave® System, which treats tooth decay using innovative technology to enhance clinical outcomes and improve dental practice workflows.
Summary not available.
Sonendo, a dental technology company, has launched a new brand campaign and website, reaffirming its commitment to endodontics and enhancing patient care. The campaign showcases clinicians utilizing the GentleWave System, emphasizing their role in advancing root canal procedures. With over one million patients treated, the campaign aims to change misconceptions about root canal therapy. The company also offers educational programs and marketing support for clinicians. CEO Bjarne Bergheim highlighted the importance of simplifying complex procedures to improve patient experiences.
Sonendo, Inc. (NYSE: SONX) announced that its subsidiary, PIPStek LLC, has filed a patent infringement lawsuit against BIOLASE, Inc. in the U.S. District Court for Delaware. The suit asserts that BIOLASE's Waterlase laser infringes on two patents owned by PIPStek. Sonendo acquired PIPStek in 2017, securing its intellectual property, which includes dental laser technologies. CEO Bjarne Bergheim emphasized their commitment to protect intellectual property and expressed confidence in a favorable court ruling.
Summary not available.
Sonendo, a dental technology leader, reported Q3 2022 financials with total revenue of $9.8 million, up 25% from Q3 2021. Consumable revenue reached $4.8 million, marking a 30% increase year-over-year. The GentleWave install base grew to approximately 935 units. A private financing round yielded $63 million. However, the gross margin declined to 24%, and the company reported a loss from operations of $14.6 million. Full-year 2022 revenue guidance is $40.5 million to $42.5 million, reflecting 22%-28% growth.
Sonendo, Inc. (NYSE: SONX), a dental technology leader, will participate in the Stifel 2022 Healthcare Conference on November 15 at 10:55 a.m. Eastern Time. An audio webcast will be available on their website. Sonendo focuses on innovative treatments for tooth decay via the patented GentleWave® System, offering less invasive procedures with improved clinical outcomes. The company also owns TDO Software, enhancing dental practice management.
Sonendo has received Health Canada regulatory approval for its GentleWave G4 System, aimed at improving the treatment of tooth decay in Canada. This next-generation technology enhances user experience with a simplified workflow and advanced features, including battery backup and multi-operatory connectivity. A recent clinical trial showed that 99.5% of patients reported no pain during procedures using GentleWave Technology. This approval marks a significant expansion of Sonendo’s product offerings in Canada, reinforcing its commitment to endodontic practices.